Summary & Overview
CPT 87426: COVID-19 Antigen Detection by Immunoassay
CPT code 87426 is a critical laboratory billing code for the detection of SARS-CoV and SARS-CoV-2 antigens, supporting the national response to COVID-19. This code covers qualitative or semiquantitative immunoassay techniques, such as EIA, ELISA, and IMCA, and is typically performed in clinical laboratories. The code is widely recognized by major payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, ensuring broad coverage for COVID-19 antigen testing across the United States.
Readers will gain insight into the clinical context of 87426, including its role in COVID-19 diagnostics, relevant laboratory settings, and payer coverage. The publication also provides benchmarks, policy updates, and an overview of related codes and diagnoses, helping stakeholders understand the evolving landscape of COVID-19 testing and reimbursement. The inclusion of common modifiers and associated taxonomies further clarifies billing and clinical application, making this summary a valuable resource for laboratory professionals, clinicians, and healthcare administrators.
CPT Code Overview
CPT code 87426 is used for the detection of infectious agent antigens, specifically severe acute respiratory syndrome coronavirus (such as SARS-CoV and SARS-CoV-2 [COVID-19]), utilizing immunoassay techniques. These methods include enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and immunochemiluminometric assay (IMCA), performed in a qualitative or semiquantitative, multiple-step format. The service falls under Pathology and Laboratory / Microbiology and is typically conducted in a laboratory setting (Place of Service 81). This code is essential for identifying COVID-19 antigens, supporting timely diagnosis and public health response.
Clinical & Coding Specifications
Clinical Context
A patient presents to their healthcare provider with symptoms suggestive of COVID-19, such as cough or fever, or has had recent exposure to a confirmed case. The provider orders a laboratory test to detect the presence of SARS-CoV-2 antigen using an immunoassay technique. The specimen is collected (typically a nasal or throat swab) and sent to a clinical laboratory (Place of Service 81) for analysis. The laboratory performs a qualitative or semiquantitative immunoassay (such as EIA, ELISA, or IMCA) to detect SARS-CoV-2 antigen. The results assist in diagnosing active COVID-19 infection, guiding further clinical management and public health measures.
Coding Specifications
- Modifier
QW: Indicates that the test is CLIA-waived, meaning it can be performed in laboratories with a CLIA Certificate of Waiver. Use modifierQWwhen the test meets CLIA waiver criteria.
| Modifier Code | Description |
|---|---|
QW | CLIA-waived test |
- Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
291U00000X | Clinical Medical Laboratory |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
- Specialties Represented:
- Clinical Medical Laboratory: Performs laboratory testing and analysis.
- Family Medicine Physician: Orders and interprets tests for patients in primary care settings.
- Internal Medicine Physician: Orders and interprets tests for adult patients, often in outpatient or inpatient settings.
Related Diagnoses
-
U07.1: COVID-19, virus identified- Used when laboratory confirmation of COVID-19 is present. Directly relevant for patients tested with
87426.
- Used when laboratory confirmation of COVID-19 is present. Directly relevant for patients tested with
-
Z20.822: Contact with and (suspected) exposure to COVID-19- Used for patients who have been exposed or suspected to have been exposed to COVID-19. Supports testing for asymptomatic or exposed individuals.
-
J12.82: Pneumonia due to coronavirus disease 2019- Used when a patient has pneumonia confirmed to be caused by COVID-19. Testing with
87426may help confirm the etiology.
- Used when a patient has pneumonia confirmed to be caused by COVID-19. Testing with
-
Z11.52: Encounter for screening for COVID-19- Used for patients undergoing screening for COVID-19, such as pre-procedural or workplace testing.
-
R05: Cough- Used for patients presenting with cough, a common symptom prompting COVID-19 testing with
87426.
- Used for patients presenting with cough, a common symptom prompting COVID-19 testing with
Related CPT Codes
-
87635: Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2- Used for molecular testing (PCR) to detect SARS-CoV-2 RNA. Often ordered for definitive diagnosis and may be used alongside or as an alternative to antigen testing.
-
87811: Infectious agent antigen detection by immunoassay with direct optical observation; SARS-CoV-2- Represents a rapid antigen test using direct optical observation. Used as an alternative to
87426for quick results.
- Represents a rapid antigen test using direct optical observation. Used as an alternative to
-
86769: Antibody detection, SARS-CoV-2- Used to detect antibodies to SARS-CoV-2, indicating past infection or immune response. Not used for acute diagnosis but may be ordered in conjunction with antigen or molecular tests.
-
86328: Immunoassay for infectious agent antibody, qualitative or semiquantitative; SARS-CoV-2- Another code for antibody testing, focusing on qualitative or semiquantitative results. Used for assessing immune status, not acute infection.
Clinical Workflow Notes:
87635and87426are commonly used as alternatives depending on whether molecular or antigen testing is preferred.87811is used for rapid antigen testing, often in point-of-care settings.86769and86328are used for antibody testing, typically not for acute diagnosis.
National Reimbursement Benchmarks
National mean rates for CPT code 87426 show that BUCA (the average commercial benchmark) is $39.20, while Medicare rates are not available in the input. Among individual commercial payers, Aetna has the highest mean rate at $47.41, and Blue Cross Blue Shield, Cigna, and UnitedHealth Group cluster around $35–$36.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies notably across payers. Aetna exhibits the tightest range ($2.33), indicating relatively consistent rates nationally. Cigna and UnitedHealth Group have the widest dispersions ($26.50 and $19.00, respectively), reflecting greater variability in contracted rates. Blue Cross Blue Shield and BUCA show moderate dispersion ($11.00 and $15.75).
The table and chart below present a full breakdown of national mean rates and percentile distributions for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.